Possible role of poly(ADP-ribose) polymerase in pathological and physiological cardiac hypertrophy

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 28, Issue 10, 2006, Pages 683-689

  Balakumar, P ^a   Singh, Manjeet ^a  

^a PUNJABI UNIVERSITY   (India)

Author keywords

5 Aminoisoquinoline; Aortic banding; Cardiac hypertrophy; Chronic swimming; PARP

Indexed keywords

5 AMINOISOQUINOLINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; EXERCISE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; VENOUS PRESSURE;

ANIMALS; AORTA, ABDOMINAL; BLOOD PRESSURE; CARDIOMEGALY; COLLAGEN; CONSTRICTION, PATHOLOGIC; ISOQUINOLINES; MALE; POLY(ADP-RIBOSE) POLYMERASES; RATS; RATS, WISTAR; RNA; SWIMMING; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33846937605     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2006.28.10.1037495     Document Type: Article

References (43)

1. Hasenfuss, G. Animal models of human cardiovascular disease, heart failure and hypertrophy. Cardiovasc Res 1998, 39: 60-76.
2. Hunter, J.J., Chein, K.R. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 1999, 341: 1276-83.
3. McMullen, J.R., Shioi, T., Zhang, L. et al. Phosphoinositide 3-kinase (p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci U S A 2003, 100: 12355-60.
4. Izumo, S., Ginard, B.N., Mahdavi, V. Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci U S A 1988, 85: 339-43.
5. Wilkins, B.J., Dai, Y.S., Bueno, O.F. et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 2004, 94: 110-8.
6. Virag, L., Szabo, C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002, 54: 375-429.
7. Chen, M., Zsengeller, Z., Xiao, C.Y., Szabo, C. Mitochondrial-to- nuclear translocation of apoptosis factor in cardiac myocytes during oxidant stress: potential role of poly(ADP-ribose) polymerase-1. Cardiovas Res 2004, 63: 682-8.
8. Ha, H.C., Snyder, S.H. Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci U S A 1999, 69: 13978-82.
9. Hong, S.J., Dawson, T.M., Dawson, V.L. Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol Sci 2004, 25(5): 259-64.
10. Pacher, P., Liaudet, L., Bai, P. et al. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 2002, 300: 862-7.
11. Szenczi, O., Kemecsei, P., Holthuijsen, M.F. et al. Poly(ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure. Biochem Pharmacol 2005, 69(5): 725-32.
12. Pacher, P., Liaudet, L., Mabley, J.G., Komjati, K., Szabo, C. Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. J Am Coll Cardiol 2002, 40: 1006-16.
13. Pacher, P., Liaudet, L., Mabley, J.G., Cziraki, A., Hasko, G., Szabo, C. Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure. Int J Mol Med 2006, 17(2): 369-75.
14. Pacher, P., Schulz, R., Liaudet, L., Szabo, C. Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci 2005, 26(6): 302-10.
15. Ungvari, Z., Gupte, S.A., Recchia, F.A., Batkai, S., Pacher, P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol 2005, 3(3): 221-9.
16. Pillai, J.B., Russell, H.M., Raman, J.S., Jeevanandam, V., Gupta M.P. Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure. Am J Physiol Heart Circ Physiol 2005, 288: H486-H496.
17. Obayashi, M., Yano, M., Kohno, M. et al. Dose-dependent effect of ang II-receptor antagonist on myocyte remodeling in rat cardiac hypertrophy. Am J Physiol Heart Circ Physiol 1997, 273: H1824-H1831.
18. Shimoyama, M., Hayashi, D., Takimoto, E. et al. Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. Circulation 1999, 100: 2449-54.
19. Medeiros, A., Oliveira, E.M., Gianolla, R., Casarini, D.E., Negrao, C.E., Brum, P.C. Swimming training increases cardiac vagal activity and induces cardiac hypertrophy in rats. Braz J Med Biol Res 2004, 37: 1909-17.
20. Pelouch, V., Kolar, F., Ostadal, B., Milerova, M., Cihak, R., Widimsky, J. Regression of chronic hypoxia induced pulmonary hypertension, right ventricular hypertrophy and fibrosis: effect of enalapril. Cardiovasc Drug Ther 1997, 11: 177-85.
21. Masutomo, K., Makino, N., Sugano, M., Miyamoto, S., Hata, T., Yanaga, T. Extracellular matrix regulation in the development of syrian cardiomyopathic bio 14.6 and bio 53.58 hamsters. J Mol Cell Cardiol 1999, 31: 1607-15.
22. Simko, F., Pelouch, V., Kyselovic, J. Captopril fails to reverse hypertrophy of the left ventricle induced by aortic insufficiency in rabbits. Physiol Res 2002, 51: 27-33.
23. Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.J. Protein measurement with folin-phenol reagent. J Biol Chem 1951, 193: 265-75.
24. Chomczynski, P., Sacchi, N. A single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162: 156-59.
25. Woodiwiss, A.J, Norton, G.R. Exercise-induced cardiac hypertrophy is associated with an increased myocardial compliance. J Appl Physiol 1995, 78(4): 1303-11.
26. Molkentin, J.D., Dorn, G.W. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 2001, 63: 391-426.
27. Geenen, D., Buttrick, P., Scheuer, J. Cardiovascular and hormonal responses to swimming and running in the rat. J Appl Physiol 1988, 65: 116-23.
28. Evangelista, F.S., Brum, P.C., Krieger, J.E. Duration-controlled swimming exercise training induces cardiac hypertrophy in mice. Braz J Med Biol Res 2003, 36: 1751-9.
29. Stamm, C., Friehs, I., Cowan, D.B. et al. Inhibition of tumor necrosis factor-α improves postischemic recovery of hypertrophied hearts. Circulation 2001, 104(Suppl I): I-350-I-355.
30. Li, J., Li, P., Feng, X. et al. Effects of losartan on pressure overload-induced cardiac gene expression profiling in rats. Clin Exp Pharmacol Physiol 2003, 30: 827-32.
31. Nagai, R., Low, R.B., Stirewalt, W.S., Alpert, N.R., Litten, R.Z. Efficiency and capacity of protein synthesis are increased in pressure overload cardiac hypertrophy. Am J Physiol Heart Circ Physiol 1988, 255: H325-H328.
32. Reddy, D.S., Singh, M., Ghosh, S., Ganguly, N.K. Role of cardiac renin-angiotensin system in the development of pressure-overload left ventricular hypertrophy in rats with abdominal aortic constriction. Mol Cell Biochem 1996, 155: 1-11.
33. Abdellatif, M., Packer, S.E., Michael, L.H., Zhang, D., Charng, M.J., Schneider, M.D. A Ras-dependent pathway regulates RNA polymerase II phosphorylation in cardiac myocytes: Implications for cardiac hypertrophy. Mol Cell Biol 1998, 18(11): 6729-36.
34. Sepodes, B., Pinto, R., Thiemermann, C., Moto-Filipe, H. Effects of 5-AIQ in a rat model of streptozotocin-induced diabetes. Med Sci Monit 2003, 9 (S1): 61-70.
35. McDonald, M.C., Mota-Filipe, H., Wright, J.A. et al. Effects of 5-aminoisoquinoline, a water-soluble, potent inhibitor of the activity of poly(ADP-ribose) polymerase on the organ injury and dysfunction caused by haemorrhagic shock. Br J Pharmacol 2000, 130: 843-50.
36. Dai, Z.K., Tan, M.S., Chai, C.Y. et al. Upregulation of endothelial nitric oxide synthase and endothelin-1 in pulmonary hypertension secondary to heart failure in aorta-banded rats. Pediatr Pulmonol 2004, 37: 249-56.
37. Osada, M., Netticadan, T., Tamura, K., Dhalla, N.S. Modification of ischemia-reperfusion induced changes in cardiac sarcoplasmic reticulum by preconditioning. Am J Physiol Heart Circ Physiol 1998, 274: H2025-H2034.
38. Anversa, P., Zhang, X., Peng, L., Capasso, J.M. Chronic coronary artery constriction leads to moderate myocyte loss and left ventricular dysfunction and failure in rats. J Clin Invest 1992, 89: 618-29.
39. Wang, X., Ren, B., Liu, S., Sentex, E., Tappia, P.S., Dhalla, N.S. Characterization of cardiac hypertrophy and heart failure due to volume overload in the rat. J App Physiol 2003, 94: 752-63.
40. Zhang, M., Xu, Y.J., Saini, H.K., Turan, B., Liu, P.P., Dhalla, N.S. Pentoxifylline attenuates cardiac dysfunction and reduces TNF-alpha level in ischemic-reperfused heart. Am J Physiol Heart Circ Physiol 2005, 289: H832-H839.
41. Weber, K.T., Brilla, C.G. Pathological hypertrophy and cardiac interstium. Fibrosis and renin angiotensin aldosterone system. Circulation 1991, 83: 1849-65.
42. Bing, O.H.L., Sem, S., Conard, C.H., Brooks, W.W. Myocardial function structure and collagen in the spontaneously hypertensive rat: Progression from compensated hypertrophy to haemodynamic impairment. Eur Heart J 1984, 5: 43-52.
43. Weber, K.T., Sun, Y., Tyagi, S.C., Cleutjens, J.P.M. Collagen network of the myocardium: Function, structure remodeling and regulatory mechanisms. J Mol Cell Cardiol 1994, 26: 279-92.